A Long Overdue Targeted Treatment for KRAS Mutations in NSCLC: Spotlight on Adagrasib

Figures & data

Table 1 Ongoing Trials of MRTX849/Adagrasib

Trial Identifier	Study Drugs	Phase	Population	Number Subjects	Primary Endpoint	Status
NCT04685135	Adagrasib vs docetaxel	3	Previously treated NSCLC	340	PFS	Recruiting
NCT05375994	VS6766 + adagrasib	1/2	NSCLC	85	ORR and DLT	Not yet recruiting
NCT04613596	Adagrasib ± pembrolizumab	2	Advanced NSCLC	250	ORR	Recruiting
NCT05162443	Adagrasib	4	Solid tumors	N/A	N/A	Available
NCT04975256 KRYSTAL 14	Adagrasib + BI1701963	1/1b	Solid tumors	100	AEs, PK, DLT	Active, not recruiting
NCT05178888 KRYSTAL 16	Adagrasib + Palbociclib	1/1b	Solid tumors	50	AEs, PK, DLT	Recruiting
NCT04330664 KRYSTAL 2	Adagrasib + TNO155	1/2	Solid tumors	86	AEs, PK	Active, not recruiting
NCT04418661	Adagrasib + SAR442720	1/2	Metastatic cancers	133	AEs, DLT, ORR, PK	Recruiting
NCT03785249 KRYSTAL 1	Adagrasib	1/2	Solid tumors	740	AEs, PK, ORR	Recruiting
NCT05272423	Sotorasib vs adagrasib	Cohort	Solid tumors	500	Geonomic mechanisms resistance	Not yet recruiting
NCT05263986	Adagrasib	1	Solid tumors	24	PK	Recruiting
NCT04793958	Adagrasib + Cetuximab vs chemotherapy	3	Advanced colorectal cancer; progression on first-line therapy	420	OS, PFS	Recruiting

Abbreviations: PFS, progression-free survival; ORR, overall response rate; DLT, dose-limiting toxicity; AE, adverse event; PK, pharmacokinetics; OS, overall survival.